KUROS BIOSCIENCES AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.89 CHF | +2.38% |
|
-8.62% | +97.42% |
| Apr. 24 | Kuros Biosciences Posts Higher Q1 Product Sales | MT |
| Apr. 17 | Kuros Biosciences AG Approves Board of Director and Committee Changes | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Kuros Biosciences AG is a Switzerland-based biotechnology company engaged in the discovery, development and commercialization of biopharmaceutical products known as Immunodrugs. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The Company has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The Company has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.
Calendar
2024-08-06
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +97.42% | 271M | |
| -2.26% | 104B | |
| +1.41% | 97.42B | |
| +0.79% | 22.2B | |
| -17.84% | 21.23B | |
| -11.11% | 18.33B | |
| -42.83% | 16.35B | |
| -17.63% | 15.06B | |
| +4.55% | 13.98B | |
| +32.11% | 11.66B |
- Stock Market
- Equities
- KURN Stock
- News Kuros Biosciences AG
- Kuros Biosciences Concludes Initial Patient Enrollment in Mid-stage Study of Bone Graft
